Biorasi, a full-service CRO powered by ProAct+, has formed an endocrinology division established to consolidate and expand Biorasi market leadership in running clinical trials in diabetes and women’s health. The new division will be led by Bill Doyle, the division manager, out of the Miami, Fla. headquarters.
“Our explosive growth in men’s and women’s health, as well as in diabetes and other endocrinology indications, has driven the decision to carve out a dedicated division,” said Doyle. “Just in the last six weeks, three major endocrinology milestones achieved include: a program we managed gained FDA approval of the Estradiol Transdermal System USP, we submitted the final study report for a novel type II diabetes therapy and we locked the database for a pivotal study in hormone replacement therapy for postmenopausal women.”
Biorasi will hire 25 to 30 employees this year for the endocrinology division. Biorasi has about 100 employees at its Aventura, Fla. headquarters, which it will outgrow soon, said chairman Boris Reznik.